IL314086B1 - Benzamides of pyrazole-amino-pyrimidine substances and their use - Google Patents

Benzamides of pyrazole-amino-pyrimidine substances and their use

Info

Publication number
IL314086B1
IL314086B1 IL314086A IL31408624A IL314086B1 IL 314086 B1 IL314086 B1 IL 314086B1 IL 314086 A IL314086 A IL 314086A IL 31408624 A IL31408624 A IL 31408624A IL 314086 B1 IL314086 B1 IL 314086B1
Authority
IL
Israel
Prior art keywords
mmol
pyrazol
amino
compound
benzamide
Prior art date
Application number
IL314086A
Other languages
English (en)
Hebrew (he)
Other versions
IL314086A (en
Inventor
Wan Zhaokui
Lawrence Vazquez Michael
Li Xiaodong
Original Assignee
Lynk Pharmaceuticals Co Ltd
Wan Zhaokui
Lawrence Vazquez Michael
Li Xiaodong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lynk Pharmaceuticals Co Ltd, Wan Zhaokui, Lawrence Vazquez Michael, Li Xiaodong filed Critical Lynk Pharmaceuticals Co Ltd
Publication of IL314086A publication Critical patent/IL314086A/en
Publication of IL314086B1 publication Critical patent/IL314086B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL314086A 2018-12-14 2019-12-16 Benzamides of pyrazole-amino-pyrimidine substances and their use IL314086B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2018/121165 WO2020118683A1 (en) 2018-12-14 2018-12-14 Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
PCT/CN2019/125552 WO2020119819A1 (en) 2018-12-14 2019-12-16 Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof

Publications (2)

Publication Number Publication Date
IL314086A IL314086A (en) 2024-09-01
IL314086B1 true IL314086B1 (en) 2026-05-01

Family

ID=71076270

Family Applications (3)

Application Number Title Priority Date Filing Date
IL314086A IL314086B1 (en) 2018-12-14 2019-12-16 Benzamides of pyrazole-amino-pyrimidine substances and their use
IL283968A IL283968B2 (en) 2018-12-14 2019-12-16 Benzamides of pyrazole-amino-pyrimidine substances and their use
IL314084A IL314084B1 (en) 2018-12-14 2019-12-16 Benzamides of pyrazole-amino-pyrimidine substances and their use

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL283968A IL283968B2 (en) 2018-12-14 2019-12-16 Benzamides of pyrazole-amino-pyrimidine substances and their use
IL314084A IL314084B1 (en) 2018-12-14 2019-12-16 Benzamides of pyrazole-amino-pyrimidine substances and their use

Country Status (14)

Country Link
US (6) US12421213B2 (cg-RX-API-DMAC7.html)
EP (1) EP3877381A4 (cg-RX-API-DMAC7.html)
JP (3) JP7459094B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250162926A (cg-RX-API-DMAC7.html)
CN (7) CN118290403A (cg-RX-API-DMAC7.html)
AU (3) AU2019399939B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011147A2 (cg-RX-API-DMAC7.html)
CA (3) CA3230071A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191188A1 (cg-RX-API-DMAC7.html)
IL (3) IL314086B1 (cg-RX-API-DMAC7.html)
MX (3) MX428809B (cg-RX-API-DMAC7.html)
SG (1) SG11202105730TA (cg-RX-API-DMAC7.html)
TW (3) TWI866940B (cg-RX-API-DMAC7.html)
WO (2) WO2020118683A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物
WO2021204159A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
CN112661655B (zh) * 2020-12-29 2022-02-18 江苏云朴医药新材料科技有限公司 一种1-氨甲基-1-环丙醇类化合物及其合成方法
EP4577535A4 (en) * 2022-08-22 2026-05-20 Hangzhou Highlightll Pharmaceutical Co Ltd JAK1/JAK2/TYK2 INHIBITORS FOR THE TOPICAL TREATMENT OF DERMATOLOGICAL DISEASES
CN115572269B (zh) * 2022-10-08 2024-05-17 广州大学 一种n-三氟异丙基唑类和吲哚化合物及其制备方法
WO2023151724A1 (zh) 2023-05-19 2023-08-17 凌科药业(杭州)有限公司 一种吡唑基-氨基-嘧啶基衍生物的晶型、制备方法及应用
CN116751191B (zh) * 2023-05-19 2025-09-16 凌科药业(杭州)有限公司 一种吡唑基-氨基-嘧啶基衍生物的晶型、制备方法及应用
CN116983312B (zh) * 2023-05-24 2024-07-05 凌科药业(杭州)有限公司 一种药物组合物、外用制剂及其制备方法、应用
WO2024239282A1 (zh) * 2023-05-24 2024-11-28 凌科药业(杭州)有限公司 一种药物组合物、外用制剂及其制备方法、应用
TW202545933A (zh) * 2024-01-26 2025-12-01 大陸商凌科藥業(杭州)有限公司 一種吡唑基-胺基-嘧啶基衍生物的苯甲醯胺的晶型、製備方法及應用
CN120917009A (zh) * 2024-01-26 2025-11-07 凌科药业(杭州)有限公司 一种吡唑基-氨基-嘧啶基衍生物的苯甲酰胺的晶型、制备方法及应用
WO2025256636A1 (zh) * 2024-06-13 2025-12-18 凌科药业(杭州)有限公司 含氮化合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012062704A1 (en) * 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
WO2013014162A1 (en) * 2011-07-28 2013-01-31 Cellzome Limited Heterocyclyl pyrimidine analogues as jak inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
WO2007005643A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxyphenylpropanamines
US20070116643A1 (en) 2005-07-01 2007-05-24 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
CN101273024A (zh) 2005-07-29 2008-09-24 康瑟特制药公司 新颖苯并[d][1,3]-二氧杂环戊烯衍生物
CA2616366A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
NZ575548A (en) * 2006-09-18 2011-09-30 Vertex Pharma Heterocyclic inhibitors of c-Met and uses thereof
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
EA020777B1 (ru) * 2007-11-16 2015-01-30 Инсайт Корпорейшн 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus
WO2012143320A1 (en) * 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
DE102011112978A1 (de) * 2011-09-09 2013-03-14 Merck Patent Gmbh Benzonitrilderivate
KR101361149B1 (ko) * 2012-07-17 2014-02-24 전남대학교산학협력단 가뭄 스트레스 저항성 관련 유전자 및 형질전환 식물체
HRP20181109T1 (hr) * 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
CN106349224A (zh) * 2016-08-03 2017-01-25 山东大学 一种含有4‑氨基‑(1h)‑吡唑结构的jak激酶抑制剂及其制备方法和应用
CN108864057B (zh) * 2017-05-16 2020-03-31 山东大学 含有4-氨基吡唑结构的jak与hdac双靶点抑制剂及其制备方法和应用
WO2020206588A1 (en) * 2019-04-08 2020-10-15 Lynk Pharmaceuticals Co., Ltd. Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
CN110330484B (zh) * 2019-07-18 2022-08-26 中国药科大学 取代类苯基嘧啶衍生物作为jak激酶抑制剂或其可药用的盐、制备方法及用途
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012062704A1 (en) * 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
WO2013014162A1 (en) * 2011-07-28 2013-01-31 Cellzome Limited Heterocyclyl pyrimidine analogues as jak inhibitors

Also Published As

Publication number Publication date
JP7802105B2 (ja) 2026-01-19
AU2024201125A1 (en) 2024-03-14
AU2024201128A1 (en) 2024-03-14
TW202039474A (zh) 2020-11-01
MX2024005744A (es) 2024-05-28
BR112021011147A2 (pt) 2021-08-31
CN118903142A (zh) 2024-11-08
CN118388457A (zh) 2024-07-26
MX2024005747A (es) 2024-05-28
IL314084A (en) 2024-09-01
TWI889396B (zh) 2025-07-01
IL283968A (en) 2021-07-29
MX428808B (es) 2025-11-13
AU2024201128B2 (en) 2025-03-06
US20230416235A1 (en) 2023-12-28
CN118290403A (zh) 2024-07-05
CN113227074A (zh) 2021-08-06
US20250115586A1 (en) 2025-04-10
US12030870B2 (en) 2024-07-09
JP7459094B2 (ja) 2024-04-01
JP2022510925A (ja) 2022-01-28
EP3877381A4 (en) 2022-08-24
US11981663B2 (en) 2024-05-14
AU2019399939A1 (en) 2021-06-24
US20240083881A1 (en) 2024-03-14
KR20210125983A (ko) 2021-10-19
US20220298144A1 (en) 2022-09-22
CN118903141A (zh) 2024-11-08
CN118955477A (zh) 2024-11-15
US12098142B2 (en) 2024-09-24
US12421213B2 (en) 2025-09-23
US20240025882A1 (en) 2024-01-25
CN119118999A (zh) 2024-12-13
TWI866940B (zh) 2024-12-21
IL314084B1 (en) 2026-05-01
US20230002362A1 (en) 2023-01-05
EP3877381A1 (en) 2021-09-15
IL283968B1 (en) 2025-05-01
US12595253B2 (en) 2026-04-07
WO2020118683A1 (en) 2020-06-18
CA3230071A1 (en) 2020-06-18
TW202440558A (zh) 2024-10-16
CA3122872A1 (en) 2020-06-18
JP7802106B2 (ja) 2026-01-19
CA3230060A1 (en) 2020-06-18
EA202191188A1 (ru) 2021-11-29
IL314086A (en) 2024-09-01
MX428809B (es) 2025-11-13
MX2021006866A (es) 2021-11-17
CN113227074B (zh) 2024-08-16
JP2024089673A (ja) 2024-07-03
KR102881668B1 (ko) 2025-11-04
AU2024201125B2 (en) 2025-03-06
TW202440559A (zh) 2024-10-16
TWI889397B (zh) 2025-07-01
IL283968B2 (en) 2025-09-01
WO2020119819A1 (en) 2020-06-18
KR20250162926A (ko) 2025-11-19
AU2019399939B2 (en) 2024-07-11
SG11202105730TA (en) 2021-06-29
JP2024088646A (ja) 2024-07-02

Similar Documents

Publication Publication Date Title
SG11202105730TA (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
IL289763A (en) Compounds, pharmaceutical compounds and methods for preparing compounds and their use
IL280963A (en) Anti-5gdf1 antibodies, compounds and methods of use
IL274276A (en) CASZ preparations and methods of use
IL279422A (en) Polymerases, preparations and methods of use
IL279423A (en) Polymerases, preparations and methods of use
GB2597163B (en) Cannabinoid compositions and methods of using
ZA202000608B (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
ZA202102034B (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
GB2582100B (en) CAS12C Compositions and methods of use
PL3668937T3 (pl) Kompozycje i zastosowania Z-1-chloro-2,3,3,3-tetrafluoroprop-1-enu
CA3244408A1 (en) Therapeutic compositions, combinations, and methods of use
ZA201906169B (en) Synthekine compositions and methods of use
IL276135A (en) Preparations and methods of use
ZA202100780B (en) Bismuth-thiol compositions and methods of use
SG11202104448WA (en) Compositions and methods
IL282533A (en) Oligosaccharide preparations and methods of using them
SG11202011041YA (en) Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
IL272834A (en) Compositions of amantadine, their preparation, and methods of use
EP3538126A4 (en) BACTERIOCIN PRODUCTION, COMPOSITIONS AND METHODS OF USE
SG11202108262VA (en) Bacterialcidal methods and compositions
HK40062036A (en) Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4-dihydropyrimidin-2-one, and methods of use thereof
HK40042752A (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
HK40065278A (en) Nanotransposon compositions and methods of use